The development of small-molecule inhibitors of the epidermalgrowth factor receptor (EGFR), such as erlotinib and gefitinib,for the treatment of advanced non–small-cell lung cancerillustrates a pattern of initial overly enthusiastic interest,subsequent critical disappointment, and eventual renewed appreciationof the clinical and mechanistic complexities surrounding theintroduction of a new therapy for cancer. Such a pattern hasbeen regrettably common in the history of oncologic therapeutics.
The initial safety and efficacy studies of erlotinib and gefitinibevoked a remarkable degree of optimism that was based on prolongedremissions and, in some cases, dramatic improvements in thequality of . . . [Full Text of this Article]
Source Information
From the Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Md.
This article has been cited by other articles:
Gordon, M. S., Matei, D., Aghajanian, C., Matulonis, U. A., Brewer, M., Fleming, G. F., Hainsworth, J. D., Garcia, A. A., Pegram, M. D., Schilder, R. J., Cohn, D. E., Roman, L., Derynck, M. K., Ng, K., Lyons, B., Allison, D. E., Eberhard, D. A., Pham, T. Q., Dere, R. C., Karlan, B. Y.
(2006). Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status. JCO
24: 4324-4332
[Abstract][Full Text]
(2005). Erlotinib Prolongs Survival in Non-Small-Cell Lung Cancer. JWatch General
2005: 2-2
[Full Text]
Previous
